Amylin's Leap of Faith
Executive Summary
Unceremoniously dumped by its partner Johnson & Johnson in early 1998, Amylin struggled to carry on developing amylin--a hormone once hyped as "the missing link" in diabetes treatment. After twice failing to produce clinical evidence that the peptide benefitted diabetic patients, Amylin laid off 80% of its employees, and fell off Nasdaq's big board. Most investors dismissed the company, and their stake in it, as a lost cause. Amylin got a second chance in March 1999, via a private Series A financing. It's too soon to say whether the leap of faith by Amylin's new investors will be rewarded. The firm's aspirations for its lead drug are more modest now than in earlier days. It has no partner, and knows uncertainty still exists in the FDA process. Meanwhile, competitors' oral drugs are helping many Type 2 diabetics.
You may also be interested in...
Approval Delays for J&J/Basilea's Ceftobiprole Shake Partnership
Basilea has become so frustrated with partner Johnson & Johnson's efforts--or lack thereof--to get anti-infective ceftobiprole past the regulators that it has resorted to arbitration. The biotech had few other options, but probably has most to lose.
Approval Delays for J&J/Basilea's Ceftobiprole Shake Partnership
Basilea has become so frustrated with partner Johnson & Johnson's efforts--or lack thereof--to get anti-infective ceftobiprole past the regulators that it has resorted to arbitration. The biotech had few other options, but probably has most to lose.
Teasing Out Next-Generation Diabetes Drugs
Many start-ups are developing diabetes drugs based on known targets which could attract Big Pharma partners and get to the clinic quickly, while a few invest in novel compounds that are either riskier or address the field's smaller subsets. Among the former are Phenomix, Plexxikon, CareX and Prosidion; among the latter are DiaKine, and DiaMedica. In all cases, these companies are looking to partner with Big Pharma, which is aggressively pursuing small-molecule drugs for diabetes.